A phase II study with low dose decitabine, a DNA hypomethylating pyrimidine analogue, in high risk MDS patients.
(1998)
Files
No attached file found for this publication.
Details
- Authors
- Affiliations
Citations
Wijermans, P., Ferrant, A., Lubbert, M., Verhoef, G., Bosly, A., Ravoet, C., & André, M. (1998). A phase II study with low dose decitabine, a DNA hypomethylating pyrimidine analogue, in high risk MDS patients. Blood, 92(10), 632A-632A. (Original work published 1998)